Production, Mechanisms, and Therapeutic Strategies of Tryptophan Metabolites in CNS Diseases
Open Access
- 1 December 2025
- journal article
- review article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 226
Abstract
Tryptophan (TRP) metabolites, which are produced from TRP via three pathways—kynurenine, 5-hydroxytryptamine, and indole—are key signaling molecules of the gut-brain axis and are involved in a variety of central nervous system (CNS) disease processes, such as Alzheimer’s disease, depression, and schizophrenia by orchestrating inflammatory responses, redox imbalances, neurotransmitter dynamics, mitochondrial dysfunction, and apoptotic/autophagic pathways. However, TRP metabolites exhibit bidirectional modulatory effects, combining different neuroprotective and neurotoxic substances, depending on their metabolic environment and concentration thresholds, posing significant challenges for therapeutic strategies. Therefore, it is important to modulate TRP metabolite production factors, including the regulation of key enzymes in metabolic pathways, the gut microbiota, hormones, and the disease pathology microenvironment, to promote the production of neuroprotective metabolites and inhibit neurotoxic metabolite production. In this review, we detail the influencing factors affecting TRP metabolite production, the regulatory role of TRP metabolites in CNS disorders, and therapeutic strategies related to TRP metabolites for CNS disorders. Targeting TRP metabolizing enzymes or remodeling the ecology of the gut microbiota could be a new strategy for the treatment of CNS diseases, providing a theoretical basis for future precision intervention in CNS diseases. Graphical AbstractKeywords
Funding Information
- Xi'an Innovation Capability Strong Foundation Plan (22XYJ0002)
This publication has 219 references indexed in Scilit:
- Amino Acid Transport Across Mammalian Intestinal and Renal EpitheliaPhysiological Reviews, 2008
- Nicotinic Acetylcholine Receptors and Nicotinic Cholinergic Mechanisms of the Central Nervous SystemAnnual Review of Pharmacology and Toxicology, 2007
- Mitochondria and neuronal activityAmerican Journal of Physiology-Cell Physiology, 2007
- A preliminary open-label study of 5-HT1A partial agonist tandospirone for behavioural and psychological symptoms associated with dementiaInternational Journal of Neuropsychopharmacology, 2006
- Serotonin as a Modulator of Glutamate- and GABA-Mediated Neurotransmission: Implications in Physiological Functions and in PathologyCurrent Neuropharmacology, 2006
- Tryptophan metabolism and oxidative stress in patients with Huntington's diseaseJournal of Neurochemistry, 2005
- Expression of indoleamine 2,3‐dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neuronsGlia, 2004
- Development of indole-3-propionic acid (OXIGON™) for alzheimer’s diseaseJournal of Molecular Neuroscience, 2002
- Correlation between cortisol level and serotonin uptake in patients with chronic stress and depressionCognitive, Affective, & Behavioral Neuroscience, 2001
- The Brain Metabolite Kynurenic Acid Inhibits α7 Nicotinic Receptor Activity and Increases Non-α7 Nicotinic Receptor Expression: Physiopathological ImplicationsThe Journal of Neuroscience, 2001